BiotechTube

Test Article A + Test Article B + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Progressive Keratoconus

Conditions

Progressive Keratoconus

Trial Timeline

Apr 6, 2018 → Aug 10, 2020

NCT ID
NCT03442751

About Test Article A + Test Article B + Placebo

Test Article A + Test Article B + Placebo is a phase 3 stage product being developed by Glaukos for Progressive Keratoconus. The current trial status is completed. This product is registered under clinical trial identifier NCT03442751. Target conditions include Progressive Keratoconus.

What happened to similar drugs?

2 of 20 similar drugs in Progressive Keratoconus were approved

Approved (2) Terminated (4) Active (14)
✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
✅Imatinib mesylateNovartisApproved
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3
🔄Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
❌FTY720 + PlaceboNovartisPhase 3
🔄BAF312 + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03442751Phase 3Completed

Competing Products

20 competing products in Progressive Keratoconus

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3
47
ABBV-8E12 + Placebo solution for IV infusion on Day 15AbbViePhase 2
27
Placebo + ABBV-8E12AbbViePhase 2
27
ABBV-8E12AbbViePhase 1
29
AZD4635 + Durvalumab + CabazitaxelAstraZenecaPhase 2
35
antisense oligonucleotide + placeboNovartisPhase 1
29
Trametinib 2 mgNovartisPre-clinical
26
EverolimusNovartisPhase 2
35
sunitinib + everolimus + chemotherapies recommended in franceNovartisPre-clinical
26
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
FTY720 + PlaceboNovartisPhase 3
32
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43
MayzentNovartisPre-clinical
26
BAF312 + PlaceboNovartisPhase 3
40
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)NovartisPhase 1/2
39